Protalix BioTherapeutics
PLX
PLX
27 hedge funds and large institutions have $3.7M invested in Protalix BioTherapeutics in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
less funds holding
Funds holding: →
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Holders
27
Holding in Top 10
–
Calls
$988K
Puts
$110K
Top Buyers
| 1 | +$2.51M | |
| 2 | +$231K | |
| 3 | +$10.9K | |
| 4 |
Renaissance Technologies
New York
|
+$2.5K |
| 5 |
ACA
Aptus Capital Advisors
Fairhope,
Alabama
|
+$1.65K |
Top Sellers
| 1 | -$162K | |
| 2 | -$49.7K | |
| 3 | -$31K | |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$26K |
| 5 |
Millennium Management
New York
|
-$21K |